Famous Patents
Felix Hoffmann, a German chemist, was searching for something to relieve his father's arthritis. In doing so, he "rediscovered" acetylsalicylic acid and in 1900, patented a stable process for developing it. Hence, we have aspirin.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178669 | Fluorescent probe for peroxynitrite A compound represented by the following general formula (I): {R1, R3, R6 and R8 are methyl groups and the like, R2 and R7 are cyano groups and the like, R | 05/15/2012 |
| 8034930 | Boron-dipyrrin compounds comprising thienyl groups, preparation method thereof and chemosensor comprising the same Disclosed are (i) a boron-dipyrrin compound having thienyl groups, (ii) a preparation method thereof and (iii) a chemosensor comprising the boron-dipyrrin compound having thienyl groups. More particularly, the present invention provides a boron-dipyrrin compound hav... | 10/11/2011 |
| 7838673 | Proteasome inhibitors The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. ... | 11/23/2010 |
| 7585973 | Process for producing folic acid derivatives This invention provides a process for efficient production of folic acid derivatives suitable for forming conjugates of anticancer drug with folic acid. It discloses a process comprising a step of reacting 2-amino-protected pteroylimidazole with γ-lower alkyl gluta... | 09/08/2009 |
| 7576201 | Electrochromic compound A compound for electrochromic devices. One such compound of the invention is dihydro-disubstituted phenazine (VI): wherein R9 is and n=1-10. ... | 08/18/2009 |
| 7560550 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives Glycosylation of 2,6-diaminopurines or silyl derivatives thereof with a compound of the structure is facilitated by the presence of an optionally silylated 1,3-dicarbonyl compound during glycosylation. Byproducts are minimi... | 07/14/2009 |
| 7365198 | Silyl compound, light emitting material, and organic light emitting device using the same Provided is an organic light emitting device capable of emitting light with high efficiency by incorporating a silyl compound in which a silyl group is directly bonded to an anthracene ring particularly into its light emitting layer. In the organic light emitting de... | 04/29/2008 |
| 7332227 | Non-volatile lubricant system for medical devices A non-volatile lubricious coating composition is provided for use with medical devices, such as hypodermic needles, catheters, and the like. The coating composition includes a first siloxane polymer having a very low viscosity less than about 50 centistokes, a secon... | 02/19/2008 |
| 7329659 | Substituted-1-phthalazinamines as vr-1 antagonists The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharm... | 02/12/2008 |
| 7253293 | Enzymatic method to produce 7-dehydropregnenolone, vitamin D3-like compounds and derivatives thereof Provided herein are enzymatic methods of producing steroid compounds such as 7-dehydropregnenolone, hydroxy derivatives thereof and vitamin D2- and D3-like compounds and derivatives thereof. Also provided are the derivatives of the vitamin D3-like compounds so gener... | 08/07/2007 |
| 7245073 | Quinoxaline derivatives, and light emitting element using thereof It is an object to provide an organic compound that has a bipolar property and also a light emitting property, and further has heat resistance. A quinoxaline derivative represented by a general formula (1) is provided. In the formula, A represents any one of ... | 07/17/2007 |
| 7198958 | Method for increasing hydrophilicity of fluorescent label compounds A fluorescent label compound of formula where Z is a reactive group that can be used for covalent coupling of the fluorescent label compound to other molecule. Either the fluorophore is a dipyrrometheneboron difl... | 04/03/2007 |
| 7179804 | Tachykinin receptor antagonists The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins ... | 02/20/2007 |
| 7164018 | Polymers based on N-carbamyl-N'-dimethylsilyl methyl-piperazine traceless linkers for the solid phase synthesis of phenyl based libraries The present invention relates to polymers characterized by novel silicon linkers based on the carbamyl piperazine moiety, methods of preparing these polymers and their use in the solid phase synthesis of compounds or libraries of compounds embracing a phenyl ring in... | 01/16/2007 |
| 7135475 | Amide substituted xanthine derivatives The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specificat... | 11/14/2006 |
| 7119080 | Boronic ester and acid compounds, synthesis and uses Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and... | 10/10/2006 |
| 7109323 | Formulation of boronic acid compounds The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provi... | 09/19/2006 |
| 7094897 | Rhodium and iridium complexes The present invention describes novel organometallic compounds which are phosphorescence emitters. Such compounds can be used as active components (=functional materials) in a series of different types of application which can be classed within the electronics indus... | 08/22/2006 |
| 7034152 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed. ... | 04/25/2006 |
| 6998484 | Synthesis of purine locked nucleic acid analogues The present invention relates to a new method for the synthesis of purine LNA (Locked Nucleic Acid) analogues which provides a higher overall yield. The method comprising a regioselective 9-N purine glycosylation reaction followed by a one-pot nucleophilic aromatic ... | 02/14/2006 |
| 6992189 | Synthesis of piperidine and piperazine compounds as CCR5 antagonists In its several embodiments, this invention discloses novel processes to prepare the compounds of formula II and formula IV: ... | 01/31/2006 |
| 6964966 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydr... | 11/15/2005 |
| 6958319 | Formulation of boronic acid compounds The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention a... | 10/25/2005 |
| 6943250 | Protected aminofunctionalized polymerization initiators and methods of making and using same Anionic polymerization initiators useful in the preparation of polymers having a protected amine functional group. The amine functionality is part of a heterocyclic radical and includes a protecting group. ... | 09/13/2005 |
| 6916925 | Dye labeled imidazoquinoline compounds Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds arc useful, inter alia, for determining the binding and/or receptor sites of the molecules. ... | 07/12/2005 |
| 6916555 | Organic luminescence device In an organic luminescence device formed of one or plural layers of organic films between an anode and a cathode, at least one layer is any one of a luminescence layer, an electron injection layer and an electron-transporting layer and is formed of at least a spiro ... | 07/12/2005 |
| 6911551 | Spiro compounds based on boron or aluminum and the use of the same in the electronics industry The present invention relates to substituted boron or aluminum spiro compounds and their use in the electronic industry. The compounds of the invention are used as electron transport material, hole blocking material and/or as host material in organic electroluminesc... | 06/28/2005 |
| 6844437 | Process for the production of tert-butyl (E)-(6-[2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsufonyl)amino]pyrimidin-5-yl]vinyl]4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate The invention concerns a process for the manufacture of tert-butyl (E)-(6-[2-4-(4-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl)-(4R,6S)-2,2-dimethyl[1,3]-dioxan-4-yl)acetate, the novel starting material used in said process and the u... | 01/18/2005 |
| 6818631 | Fungicidal pyrimidine derivatives Fungicidal pyrimidine derivatives and the use as a fungicide of the compounds of formula (1): wherein R1 is H, C1-C6alkyl, C2-C6alkenyl, C2-C6 | 11/16/2004 |
| 6815514 | Catalysts The invention describes ligands of formula (I), wherein LIG represents an η5-ligand substituted by a group R1 and a group (R″)m; X represents a 1 to 3 atom bridge; Y represents a nitrogen or phosphorus atom; Z represents a carbon,... | 11/09/2004 |
| 6787544 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same Nitrogen-containing heterocyclic carboxamide derivatives represented by the following general formula: wherein ring A is a substituted or unsubstituted pyrazine, pyrimidine, pyridazine or triazine ring; R1 is ... | 09/07/2004 |
| 6774130 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 08/10/2004 |
| 6747033 | Fungicidal triazolopyrimid-7-ylideneamines Compounds of formula I in which R1 is alkyl, alkoxyalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkadienyl, haloalkyl, trihydrocarbylsilyl, formyl, alkanoyl or alkoxycarbonyl group being attached either to... | 06/08/2004 |
| 6747150 | Boronic ester and acid compounds, synthesis and uses Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and ... | 06/08/2004 |
| 6737124 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion Chiral nonracemic, chiral racemic and achiral compounds useful as component of LC compositions which have a silane tail group which is partially fluorinated. The silane tail group comprises a perfluoroalkyl group. The silane tail group of this invention has the form... | 05/18/2004 |
| 6727241 | Anti-inflammatory compositions and methods of use The present invention is directed to pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using ... | 04/27/2004 |
| 6699835 | Formulation of boronic acid compounds The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention... | 03/02/2004 |
| 6699855 | Inhibitors of hepatitis C virus NS3 protease The present invention relates to compounds of Formula (I): ##STR1## wherein A1 is methylene, ethylene or propylene group and A2 is N or CR5, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable ... | 03/02/2004 |
| 6696447 | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain The present application describes compounds of general formula I ##STR1## where R1 is selected from any one of pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; and where each R1 heteroaromatic ring may optionally and independen... | 02/24/2004 |
| 6680401 | Hydroboronation process The invention relates to processes for the synthesis of aryl or alkene borates which comprises reacting: (i) an olefinic compound having a halogen or halogen-like substituent in a vinylic substitution position, or (ii) an aromatic ring having a halogen or... | 01/20/2004 |
